Intraperitoneally administered chlorite-oxidized oxyamylose (COAM) provided protection of mice against intranasal infection with several influenza virus strains. Treated animals invariably showed a reduced consolidation of the lungs and, in the case of infection with lethal strains of virus, also a delay in mortality. With a small dose of influenza A/PR8 virus, an increase in final survival rate could be observed. The effect of COAM on influenza virus infection lasted for at least 4 to 8 days. Inhibition of lung consolidation was not paralleled by a decrease in virus multiplication in the lung. The significance of this finding in relation to the mechanism of the antiviral action of COAM is discussed.
Intraperitoneally administered chlorite-oxidized oxyamylose (COAM) provided protection of mice against intranasal infection with several influenza virus strains. Treated animals invariably showed a reduced consolidation of the lungs and, in the case of infection with lethal strains of virus, also a delay in mortality. With a small dose of influenza A/PR8 virus, an increase in final survival rate could be observed. The effect of COAM on influenza virus infection lasted for at least 4 to 8 days. Inhibition of lung consolidation was not paralleled by a decrease in virus multiplication in the lung. The significance of this finding in relation to the mechanism of the antiviral action of COAM is discussed.
In previous papers, we described the antiviral effect of polyacetal-carboxylic acids, of which chlorite-oxidized oxyamylose (COAM) is a representative (1, 2) . Intraperitoneal administration of COAM can protect mice against several systemic experimental viral infections. It also acts against intranasal infection with influenza virus (A/PR8-strain). For several reasons, we decided to explore further the latter effect. Firstly, the inhibition of myxovirus pathology by systemic administration of polyanions has only sporadically and irregularly been observed. Specifically, it was found that polyacrylic acid could delay mortality of mice infected with influenza A/PR8 (A. Billiau and E. De Clercq, unpublished data) but did not increase the survival rate. The very potent interferon inducer polyriboinosinic-ribocytidylic acid (In.Cn) was found to give weak protection in mice against one (B/Maryland) out of four tested influenza virus strains (4) . Therefore, we wanted to know whether COAM had a systematic effect against more than one type of influenza virus and whether such an effect would be of long duration. Secondly, the pathogenesis and pathology of influenza virus infection in mice are limited to a single organ. Therefore, we thought that this system, rather than any other one, might help to clarify the mechanism whereby the polymer inhibits viral disease. Finally, we thought that the system presented a certain interest for its possible implications as to the practical applicability of this type of compound in myxovirus infections in their natural host. The antiviral effect of COAM was measured by drawing mortality-time graphs for both treated and control groups of animals and by graphically determining the time when 50% of the animals had died. Unless stated otherwise, the animals were observed for 3 weeks post infection, and the excess survival percentage of treated over control groups was taken as a second criterion. In addition, the degree of lung consolidation in mice sacrificed at different times after challenge with influenza virus was evaluated by the method of Horsfall (3) . The animals were anesthesized and killed by section of the abdominal aorta to avoid aspiration of blood in the lungs. One-fourth of the lung consolidated was rated as 1, one-half as 2, three-fourths as 3, and complete consolidation as 4. The consolidation ratio of a group, e.g., of five mice with consolidation degrees of 2, 3, 3, 4, and 4, respectively, was calculated as 0.80 (80%) according to the following formula: (2 + 3 + 3 + 4 + 4)/(5 X 4) = 0.80. (1, 2) .
RESULTS
On the other hand, no effect was noted when the drug was given 1 or 2 days after the virus (1). To determine whether similar time-effect relationships would exist for respiratory myxovirus infections, groups of 11 to 12 mice were given 2 mg of COAM intraperitoneally. A dose of 2.5 LDbo of influenza A/PR8 virus was given intranasally at different times before or after the drug. The pooled results of two experiments are summarized in Fig. 2 mice infected with different influenza virus strains.
To investigate the effect of COAM on pathology induced by influenza virus strains which were not lethal or were slightly lethal for mice, groups of 12 mice were injected intraperitoneally with 2 mg of COAM. One day later they were given influenza virus of different strains intranasally in different doses as indicated in Table 1 . Six days after virus inoculation, the mice were autopsied and lung lesions were scored. For each group, consolidation ratios were calculated. The data show that for each strain of influenza virus tested, i.e., A/PR8, A/NWS, A2/HK, and B/Neth, an inhibition of the consolidation ratio could be observed. These data corroborate the observations on the delay of mortality. With a 10 times higher dose, no effect at all was observed, although the consolidation ratio in these groups was clearly reduced. These results plead against the interferon mechanism being the mediator of the antiviral effect of COAM. Indeed, interferon acts through inhibition of intracellular virus replication, and this inhibition is independent from the input multiplicity. It may be argued that a decrease in virus replication, too small to be measured by our technique, may cause a measurable decrease in lesion score. However, decreasing the dose of virus with a factor 10 times caused a clearly measurable decrease in virus titer at days 3 and 6. This decrease corresponded to an inhibition in lesion score, comparable to that obtained by COAM treatment. It seems probable, therefore, that a mechanism other than mere suppression of viral replication by interferon must be responsible for the inhibition of lung consolidation. Whatever the mechanism may be, it must be triggered early during viral infection, as indicated by the fact that COAM must be injected before the virus inoculation to cause a measurable effect.
In a separate study (Billiau, Muyembe, and De Somer, in preparation), we found that intraperitoneal injection of various polycarboxylates, including COAM, protects mice against experimental infection with mengovirus by mobilizing some host defense mechanism. Although the polyanions did induce circulating interferon, the experimental evidence again showed that the larger part of resistance to mengovirus infection was not VOL. 21, 1971 interferon-mediated but originated in the retention of challenge virus within the peritoneal cavity.
It may be speculated that such trapping of virus may result from increased phagocytosis of virus, or killing, or both, by peritoneal macrophages. A similar activation of reticuloendothelial cells of the lungs might account for the observed effects on influenza virus infection.
